Compare Invesco S&P 500 Low Volatility ETF (SPLV) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco S&P 500 Low Volatility ETF vs Zimmer Biomet Holdings Inc — how do they compare? Invesco S&P 500 Low Volatility ETF trades at $72 (market cap $6.94B), while Zimmer Biomet Holdings Inc trades at $89.52 (market cap $16.95B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 2.4× Invesco S&P 500 Low Volatility ETF's market cap, and Zimmer Biomet Holdings Inc pays a 1.08% dividend while Invesco S&P 500 Low Volatility ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco S&P 500 Low Volatility ETF for 123 Days and Zimmer Biomet Holdings Inc for 89 Days on average.
| SPLV | ZBH | |
|---|---|---|
Market Cap | $6.94B | $16.95B |
Volume | 1,663,703 | 2,505,240 |
52-Week High | $77.97 | $103.98 |
52-Week Low | $70.30 | $79.58 |
Typical Hold Time | 123 Days | 89 Days |
Sector | — | Health |
Enterprise Value | — | $24.02B |
Dividend Yield | — | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SPLV trades at $71.99, up 1.08% with a bearish technical outlook from moving averages. The ETF's sector overweights in Utilities, Real Estate, and Financials have contributed to underperformance versus the S&P 500. Recent dividend payments of $0.14 provide income support, while technical indicators show mixed signals with neutral oscillators.
Outlook remains cautious due to sector headwinds and unappealing growth-adjusted valuation. The fund's low-volatility focus offers defensive positioning amid market uncertainty, though continued underperformance relative to broader market indexes presents near-term challenges for total return investors.
Zimmer Biomet (ZBH) trades at $88.49, down 1.33% today, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $2.07 surpassing the $2.01 estimate. Revenue growth is steady, reaching $8.23B in 2025, though net income margin has moderated to 9.48%. A quarterly dividend of $0.24 was declared, payable in October 2026. Analyst consensus price target is $103.11, implying potential upside from current levels.
The outlook is mixed: solid fundamentals and earnings momentum support long-term value, but technical weakness and elevated debt levels pose near-term risks. Investment appeal hinges on execution of commercial transformation and robotics adoption offsetting competitive pressures. Key risks include margin compression and macroeconomic sensitivity affecting procedure volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Invesco S&P 500 Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the "index Provider") compiles, maintains and calculates the underlying index, which is designed to measure the performance of the 100 least volatile constituents of the S&P 500 ® Index over the past 12 months as determined by the index Provider.
Read more on SPLV →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
